MCID: HPT004
MIFTS: 43

Hepatic Coma

Categories: Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Coma

MalaCards integrated aliases for Hepatic Coma:

Name: Hepatic Coma 12 54 15 71
Hepatic Encephalopathy 43 71
Hepatocerebral Intoxication 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12550
MeSH 43 D006501
SNOMED-CT 67 72836002
ICD10 32 K72.91
UMLS 71 C0019147 C0019151

Summaries for Hepatic Coma

MalaCards based summary : Hepatic Coma, also known as hepatic encephalopathy, is related to viral hepatitis and hepatitis a. An important gene associated with Hepatic Coma is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Arginine biosynthesis and FOXA2 and FOXA3 transcription factor networks. The drugs Metformin and Propofol have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are homeostasis/metabolism and liver/biliary system

Related Diseases for Hepatic Coma

Diseases related to Hepatic Coma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 451)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 32.6 GPT F2 ALB AFP
2 hepatitis a 31.1 GPT F2 ALB AFP
3 hepatic encephalopathy 30.5 TSPO GPT F2 ALB
4 acute liver failure 30.5 TSPO GPT F2 ALB
5 intracranial hypertension 30.3 SERPINC1 F2 ALB
6 portal hypertension 30.3 GPT F2 ALB
7 hepatorenal syndrome 30.3 GPT F2 ALB
8 acute cystitis 30.3 GPT F2 ALB
9 infantile liver failure syndrome 1 30.2 GPT F2 ALB
10 portal vein thrombosis 30.2 SERPINC1 F2 AFP
11 active peptic ulcer disease 30.2 F2 ALB
12 liver disease 30.1 GPT F2 ALB AFP
13 acute kidney failure 30.1 GPT F2 ALB
14 non-a-e hepatitis 30.1 F2 ALB
15 cholestasis 30.1 GPT F2 ALB
16 bilirubin metabolic disorder 30.0 GPT F2 ALB
17 schistosomiasis 29.9 GPT F2 ALB
18 wilson disease 29.9 GPT F2 ALB
19 autoimmune hepatitis 29.9 GPT F2 ALB
20 liver cirrhosis 29.9 SERPINC1 GPT F2 ALB AFP
21 peliosis hepatis 29.9 GPT AFP
22 cholangitis 29.9 GPT F2 ALB
23 hepatitis e 29.8 GPT F2 ALB
24 alcoholic hepatitis 29.7 GPT F2 ALB
25 papilledema 29.7 SERPINC1 F2 ALB
26 eclampsia 29.7 SERPINC1 F2 ALB
27 cholecystitis 29.6 GPT F2 ALB
28 kwashiorkor 29.6 GPT F2 ALB
29 aspiration pneumonia 29.6 GPT F2 ALB
30 exanthem 29.6 GPT F2 ALB
31 biliary atresia 29.6 GPT F2 ALB
32 disseminated intravascular coagulation 29.6 SERPINC1 GPT F2
33 inherited metabolic disorder 29.5 GPT F2 ALB
34 metabolic acidosis 29.5 GPT F2 ALB
35 alcoholic liver cirrhosis 29.4 GPT F2 ALB AFP
36 hepatitis b 29.4 GPT F2 ALB AFP
37 fatty liver disease 29.3 GPT ALB ACACA
38 stroke, ischemic 29.3 TSPO SERPINC1 F2 ALB
39 pre-eclampsia 29.2 SERPINC1 F2 ALB AFP
40 thrombocytopenia 29.2 SERPINC1 GPT F2 ALB
41 esophageal varix 29.2 SERPINC1 GPT F2 ALB AFP
42 hypersplenism 29.1 SERPINC1 GPT F2 ALB
43 congenital extrahepatic portosystemic shunt 11.5
44 ocular motor apraxia 11.3
45 hepatic veno-occlusive disease 11.2
46 encephalopathy 10.5
47 peritonitis 10.4
48 antipyrine metabolism 10.4 F2 ALB
49 necrotizing gastritis 10.3 F2 ALB
50 hepatoportal sclerosis 10.3 GPT F2

Graphical network of the top 20 diseases related to Hepatic Coma:



Diseases related to Hepatic Coma

Symptoms & Phenotypes for Hepatic Coma

MGI Mouse Phenotypes related to Hepatic Coma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ACACA AFP ALB DBI F2 GOT1
2 liver/biliary system MP:0005370 9.1 ACACA AFP ALB DBI SERPINC1 TSPO

Drugs & Therapeutics for Hepatic Coma

Drugs for Hepatic Coma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 318)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
8
Cefoxitin Approved Phase 4 35607-66-0 441199
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
11
Azithromycin Approved Phase 4 83905-01-5 55185 447043
12
Vancomycin Approved Phase 4 1404-90-6 441141 14969
13
Insulin aspart Approved Phase 4 116094-23-6 16132418
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
15 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
19
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
20
Histamine Approved, Investigational Phase 4 51-45-6 774
21
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
22
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
23
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
24
Promethazine Approved, Investigational Phase 4 60-87-7 4927
25
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
26
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
27
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
28
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
29
Azathioprine Approved Phase 4 446-86-6 2265
30
Atorvastatin Approved Phase 4 134523-00-5 60823
31
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
32
Tranexamic Acid Approved Phase 4 1197-18-8 5526
33
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
34
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
35
Lactulose Approved Phase 4 4618-18-2 11333
36
Tolvaptan Approved Phase 4 150683-30-0 216237
37
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
38
Ethanol Approved Phase 4 64-17-5 702
39
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
40
Lorazepam Approved Phase 4 846-49-1 3958
41
Phenylalanine Approved, Investigational, Nutraceutical Phase 4 63-91-2 6140
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
43
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
44
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
45 Hypoglycemic Agents Phase 4
46 Anesthetics, General Phase 4
47 Adjuvants, Anesthesia Phase 4
48 Anesthetics, Intravenous Phase 4
49 Antitubercular Agents Phase 4
50 Amoxicillin-Potassium Clavulanate Combination Phase 4

Interventional clinical trials:

(show top 50) (show all 320)
# Name Status NCT ID Phase Drugs
1 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study Unknown status NCT03077217 Phase 4 Rifaximin
2 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
3 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
4 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
5 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
6 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
7 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
8 Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Unknown status NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
9 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
10 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
11 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
12 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
13 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
14 Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Completed NCT01559519 Phase 4 Albumin
15 High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
16 Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study Completed NCT00955500 Phase 4
17 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
18 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
19 A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Lactulose
20 The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
21 Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
22 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
23 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
24 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
25 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
26 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
27 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
28 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
29 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
30 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
31 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
32 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
33 Study of the Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4
34 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
35 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
36 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
38 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
39 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
40 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
41 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
42 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
43 Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. Not yet recruiting NCT04073290 Phase 4 Rifaximin 550 MG Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 MG/ML Oral Solution
44 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
45 Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology Terminated NCT01824589 Phase 4
46 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
47 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
48 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
49 Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
50 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose

Search NIH Clinical Center for Hepatic Coma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Kanamycin Sulfate
Lactulose
NEOMYCIN SO4 PWDR

Cochrane evidence based reviews: hepatic encephalopathy

Genetic Tests for Hepatic Coma

Anatomical Context for Hepatic Coma

MalaCards organs/tissues related to Hepatic Coma:

40
Liver, Brain, Testes, Kidney, Cortex, Colon, Heart

Publications for Hepatic Coma

Articles related to Hepatic Coma:

(show top 50) (show all 9088)
# Title Authors PMID Year
1
Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. 54 61
16563564 2006
2
The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. 54 61
12020611 2002
3
Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. 54 61
11929388 2002
4
Acute liver failure. 54 61
11132456 1999
5
The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study. 54 61
9347201 1997
6
[Severe Amanita phalloides poisoning in a 7-year-old girl]. 54 61
8348662 1993
7
"Peripheral-type" (mitochondrial) benzodiazepine receptors in hepatic encephalopathy. 54 61
7748297 1993
8
Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. 54 61
1530786 1992
9
Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. 54 61
2161396 1990
10
Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens. 61
31688311 2020
11
BabaoDan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in rats. 61
31622746 2020
12
Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. 61
31688303 2020
13
Pro-inflammatory cytokines serve as communicating molecules between the liver and brain for hepatic encephalopathy pathogenesis and Lycium barbarum polysaccharides protection. 61
31693919 2020
14
Pathophysiology of Acute Liver Failure. 61
31840297 2020
15
Acute Hepatic Failure and Nutrition. 61
31872503 2020
16
Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. 61
31440997 2020
17
Prevalence of cryptococcal antigenemia in hospitalized patients with liver cirrhosis. 61
31075793 2020
18
Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. 61
31464790 2020
19
Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant. 61
31220352 2020
20
The Development and Outcome of Acute-on-Chronic Liver Failure After Surgical Interventions. 61
31693788 2020
21
Optic nerve sheath diameter in children with acute liver failure: A prospective observational pilot study. 61
31549476 2020
22
Cerebral edema and liver disease: classic perspectives and contemporary hypotheses on mechanism. 61
32035166 2020
23
cGMP signaling pathway in hepatic encephalopathy neuroinflammation and cognition. 61
31869775 2020
24
Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. 61
31211875 2020
25
The association between hepatic encephalopathy/minimal hepatic encephalopathy and depressive and anxiety disorders: a systematic review. 61
31868516 2020
26
Efficacy and Safety of Sodium Benzoate in The Management of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood-A Double-blind Randomized Controlled Trial. 61
31978010 2020
27
Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH). 61
31537030 2020
28
Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage. 61
31222830 2020
29
Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy. 61
31582327 2020
30
Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor β1. 61
31734229 2020
31
Hepatic Encephalopathy and Nutrition Influences: A Narrative Review. 61
31872484 2020
32
A Case of Intractable Hepatic Encephalopathy with a Large Portosystemic Shunt Successfully Treated Using Shunt-preserving Disconnection of the Portal and Systemic Circulation. 61
32009096 2020
33
Hepatitis A virus-associated fulminant hepatitis with human immunodeficiency virus coinfection. 61
31543437 2020
34
Serum Osmolality, Cerebrospinal Fluid Specific Gravity, and Overt Hepatic Encephalopathy Severity in Patients with Liver Failure. 61
32020734 2020
35
Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis. 61
31338724 2020
36
Performance of scoring systems for predicting re-admission rates in Cirrhosis of liver patients with hepatic encephalopathy admitted in General medical ICU: A single Centre, observational study. 61
31979847 2020
37
A comparative Cross Sectional Study to estimate the serum zinc levels among Ethanol Related Decompensated Chronic Liver Disease patients with & without Hepatic Encephalopathy. 61
31979853 2020
38
Study of correlation of serum prolactin levels with severity of liver disease and its association with Hepatic Encephalopathy in patients of cirrhosis liver. 61
31979857 2020
39
Outcomes of lactulose plus branched-chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. 61
31943593 2020
40
Transcranial Doppler waveform changes due to increased cerebrovascular resistance and raised intracranial pressure in a patient with cirrhosis: A difference in shapes, not in numbers. 61
31774180 2020
41
Usefulness of autotaxin for the complications of liver cirrhosis. 61
31933517 2020
42
Generation and characterization of three clones (NCCSi007A, NCCSi007B and NCCSi007C) of an integration free induced Pluripotent Stem Cell line from a patient with alcoholic liver cirrhosis of Indian ethnicity. 61
31862609 2020
43
[Risk factors of cirrhosis combined with sarcopenia and their impact on clinical outcomes]. 61
32023700 2020
44
Accuracy of Physical Examination and Imaging Findings for the Diagnosis of Elevated Intracranial Pressure. 61
31994795 2020
45
Endovascular Transjugular Occlusion of Congenital Intrahepatic Portosystemic Venous Shunt Using Simultaneous Fluoroscopy and Transabdominal Ultrasound Guidance: Report of 2 Cases. 61
29674011 2020
46
Liver transplant candidates have impaired quality of life across health domains as assessed by computerized testing. 61
31558420 2020
47
Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. 61
31849218 2020
48
Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis. 61
32004593 2020
49
Lower 90-day Hospital Readmission Rates for Esophageal Variceal Bleeding After TIPS: A Nationwide Linked Analysis. 61
30829905 2020
50
A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding. 61
31960441 2020

Variations for Hepatic Coma

Expression for Hepatic Coma

Search GEO for disease gene expression data for Hepatic Coma.

Pathways for Hepatic Coma

Pathways related to Hepatic Coma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.67 GPT GOT1
2 10.44 F2 ALB AFP
3
Show member pathways
10.41 TSPO DBI
4
Show member pathways
10.07 GPT GOT1

GO Terms for Hepatic Coma

Cellular components related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.5 TSPO SERPINC1 GPT GOT1 F2 DBI
2 blood microparticle GO:0072562 9.33 SERPINC1 F2 ALB
3 endoplasmic reticulum lumen GO:0005788 9.02 SERPINC1 F2 DBI ALB AFP

Biological processes related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of reactive oxygen species metabolic process GO:2000379 9.26 TSPO F2
2 regulation of blood coagulation GO:0030193 9.16 SERPINC1 F2
3 transport GO:0006810 8.96 ALB AFP
4 cellular protein metabolic process GO:0044267 8.92 SERPINC1 F2 ALB AFP

Molecular functions related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 9.16 ALB AFP
2 transaminase activity GO:0008483 8.96 GPT GOT1
3 pyridoxal phosphate binding GO:0030170 8.8 GPT GOT1 ALB

Sources for Hepatic Coma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....